Serum Level of KL-6 as a Marker of Interstitial Lung Disease in Patients with Juvenile Systemic Sclerosis

Richard Veselý, Veronika Vargová, Angelo Ravelli, Margherita Massa, Eduard Olekšák, Rosanna D'Alterio, Alberto Martini, Fabrizio De Benedetti

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

Objective. Serum KL-6 has been found to be elevated in diseases characterized by diffuse interstitial lung involvement. The purpose of this study was to evaluate serum KL-6 as a marker of interstitial lung disease (ILD) in patients' with juvenile systemic sclerosis (JSS). Methods. Serum concentrations of KL-6 were measured with an immunoassay in 39 serum samples from 12 children with diffuse cutaneous form of JSS (6 patients with and 6 patients without ILD) and from 20 healthy controls comparable for age. In patients sampled serially, the relationship of KL-6 concentrations with the severity of ILD and its response to treatment were evaluated. Results. Serum concentrations of KL-6 were significantly higher in patients with ILD (1687 ± 979 IU/ml) than in patients without (345 ± 95 IU/ml, p <0.01) and healthy controls (311 ± 114 IU/ml, p <0.001). Serum KL-6 concentrations of patients without ILD were not statistically different from those of healthy controls. We found a significant correlation of serum KL-6 concentrations with vital capacity and with diffusing capacity for carbon monoxide (DLCO). Analysis of individual patients showed that serum concentrations of KL-6 were correlated with ILD severity and its response to treatment. Conclusion. Measurement of serum KL-6 concentration is a useful noninvasive marker of pulmonary fibrosis in children with JSS. Its advantages over conventional methods of ILD assessment, such as pulmonary function test and high-resolution computerized tomography, are that it is easy to quantify and to measure repeatedly and it does not need children's cooperation.

Original languageEnglish
Pages (from-to)795-800
Number of pages6
JournalJournal of Rheumatology
Volume31
Issue number4
Publication statusPublished - Apr 2004

Fingerprint

Systemic Scleroderma
Interstitial Lung Diseases
Serum
Pulmonary Fibrosis
Respiratory Function Tests
Vital Capacity
Carbon Monoxide
Immunoassay
Tomography
Lung
Skin
Therapeutics

Keywords

  • Interstitial lung disease
  • Juvenile systemic sclerosis
  • KL-6

ASJC Scopus subject areas

  • Rheumatology
  • Immunology

Cite this

Serum Level of KL-6 as a Marker of Interstitial Lung Disease in Patients with Juvenile Systemic Sclerosis. / Veselý, Richard; Vargová, Veronika; Ravelli, Angelo; Massa, Margherita; Olekšák, Eduard; D'Alterio, Rosanna; Martini, Alberto; De Benedetti, Fabrizio.

In: Journal of Rheumatology, Vol. 31, No. 4, 04.2004, p. 795-800.

Research output: Contribution to journalArticle

@article{8648083adf3e459dab8b0371e745316d,
title = "Serum Level of KL-6 as a Marker of Interstitial Lung Disease in Patients with Juvenile Systemic Sclerosis",
abstract = "Objective. Serum KL-6 has been found to be elevated in diseases characterized by diffuse interstitial lung involvement. The purpose of this study was to evaluate serum KL-6 as a marker of interstitial lung disease (ILD) in patients' with juvenile systemic sclerosis (JSS). Methods. Serum concentrations of KL-6 were measured with an immunoassay in 39 serum samples from 12 children with diffuse cutaneous form of JSS (6 patients with and 6 patients without ILD) and from 20 healthy controls comparable for age. In patients sampled serially, the relationship of KL-6 concentrations with the severity of ILD and its response to treatment were evaluated. Results. Serum concentrations of KL-6 were significantly higher in patients with ILD (1687 ± 979 IU/ml) than in patients without (345 ± 95 IU/ml, p <0.01) and healthy controls (311 ± 114 IU/ml, p <0.001). Serum KL-6 concentrations of patients without ILD were not statistically different from those of healthy controls. We found a significant correlation of serum KL-6 concentrations with vital capacity and with diffusing capacity for carbon monoxide (DLCO). Analysis of individual patients showed that serum concentrations of KL-6 were correlated with ILD severity and its response to treatment. Conclusion. Measurement of serum KL-6 concentration is a useful noninvasive marker of pulmonary fibrosis in children with JSS. Its advantages over conventional methods of ILD assessment, such as pulmonary function test and high-resolution computerized tomography, are that it is easy to quantify and to measure repeatedly and it does not need children's cooperation.",
keywords = "Interstitial lung disease, Juvenile systemic sclerosis, KL-6",
author = "Richard Vesel{\'y} and Veronika Vargov{\'a} and Angelo Ravelli and Margherita Massa and Eduard Olekš{\'a}k and Rosanna D'Alterio and Alberto Martini and {De Benedetti}, Fabrizio",
year = "2004",
month = "4",
language = "English",
volume = "31",
pages = "795--800",
journal = "Journal of Rheumatology",
issn = "0315-162X",
publisher = "Journal of Rheumatology",
number = "4",

}

TY - JOUR

T1 - Serum Level of KL-6 as a Marker of Interstitial Lung Disease in Patients with Juvenile Systemic Sclerosis

AU - Veselý, Richard

AU - Vargová, Veronika

AU - Ravelli, Angelo

AU - Massa, Margherita

AU - Olekšák, Eduard

AU - D'Alterio, Rosanna

AU - Martini, Alberto

AU - De Benedetti, Fabrizio

PY - 2004/4

Y1 - 2004/4

N2 - Objective. Serum KL-6 has been found to be elevated in diseases characterized by diffuse interstitial lung involvement. The purpose of this study was to evaluate serum KL-6 as a marker of interstitial lung disease (ILD) in patients' with juvenile systemic sclerosis (JSS). Methods. Serum concentrations of KL-6 were measured with an immunoassay in 39 serum samples from 12 children with diffuse cutaneous form of JSS (6 patients with and 6 patients without ILD) and from 20 healthy controls comparable for age. In patients sampled serially, the relationship of KL-6 concentrations with the severity of ILD and its response to treatment were evaluated. Results. Serum concentrations of KL-6 were significantly higher in patients with ILD (1687 ± 979 IU/ml) than in patients without (345 ± 95 IU/ml, p <0.01) and healthy controls (311 ± 114 IU/ml, p <0.001). Serum KL-6 concentrations of patients without ILD were not statistically different from those of healthy controls. We found a significant correlation of serum KL-6 concentrations with vital capacity and with diffusing capacity for carbon monoxide (DLCO). Analysis of individual patients showed that serum concentrations of KL-6 were correlated with ILD severity and its response to treatment. Conclusion. Measurement of serum KL-6 concentration is a useful noninvasive marker of pulmonary fibrosis in children with JSS. Its advantages over conventional methods of ILD assessment, such as pulmonary function test and high-resolution computerized tomography, are that it is easy to quantify and to measure repeatedly and it does not need children's cooperation.

AB - Objective. Serum KL-6 has been found to be elevated in diseases characterized by diffuse interstitial lung involvement. The purpose of this study was to evaluate serum KL-6 as a marker of interstitial lung disease (ILD) in patients' with juvenile systemic sclerosis (JSS). Methods. Serum concentrations of KL-6 were measured with an immunoassay in 39 serum samples from 12 children with diffuse cutaneous form of JSS (6 patients with and 6 patients without ILD) and from 20 healthy controls comparable for age. In patients sampled serially, the relationship of KL-6 concentrations with the severity of ILD and its response to treatment were evaluated. Results. Serum concentrations of KL-6 were significantly higher in patients with ILD (1687 ± 979 IU/ml) than in patients without (345 ± 95 IU/ml, p <0.01) and healthy controls (311 ± 114 IU/ml, p <0.001). Serum KL-6 concentrations of patients without ILD were not statistically different from those of healthy controls. We found a significant correlation of serum KL-6 concentrations with vital capacity and with diffusing capacity for carbon monoxide (DLCO). Analysis of individual patients showed that serum concentrations of KL-6 were correlated with ILD severity and its response to treatment. Conclusion. Measurement of serum KL-6 concentration is a useful noninvasive marker of pulmonary fibrosis in children with JSS. Its advantages over conventional methods of ILD assessment, such as pulmonary function test and high-resolution computerized tomography, are that it is easy to quantify and to measure repeatedly and it does not need children's cooperation.

KW - Interstitial lung disease

KW - Juvenile systemic sclerosis

KW - KL-6

UR - http://www.scopus.com/inward/record.url?scp=1842425819&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=1842425819&partnerID=8YFLogxK

M3 - Article

C2 - 15088311

AN - SCOPUS:1842425819

VL - 31

SP - 795

EP - 800

JO - Journal of Rheumatology

JF - Journal of Rheumatology

SN - 0315-162X

IS - 4

ER -